Stock·NASDAQ·Healthcare
Illumina Inc. (ILMN)
- Market cap
- $40.93B
- P/E
- 50.57
- Dividend yield
- None
- Street target
- $272.50median of 21 analysts
- 52-week range
- $94.00 $309.35
ILMN stock forecast today
Where ILMN stands today, and what CleaRank Financial AI makes of it.
ILMN at a glance
Illumina Inc. (ILMN): Buy, 67/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($243.41 and $173.52).
- Earnings ILMN beat estimates in 5 of the 5 reports in our data, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $592.9M and bought $1.6M over the last 18 months.
- Valuation P/E of 50.6 against 31.9 for the Healthcare sector: a premium to peers (+59%).
Figures as of October 26, 2026.
CleaRank Financial AI
Illumina Inc. (ILMN) carries a CleaRank rating of Buy and a model score of 67/100.
Trend contributes most to that score: the price is 56.20% above its 200-day average and 11.35% above its 50-day average, and the 50-day average is 40.28% above the 200-day. Valuation is the largest drag. The P/E of 50.57 is 58.5% above the sector median (a premium to peers), and the P/S of 9.05 is 166.2% above the sector median. The 50-day average sits at $243.41 and the 200-day at $173.52. Across the past year the price climbed 170.74%.
Only on CleaRank
Figures we compute ourselves from ILMN's own price, earnings and insider-filing history. Tap one to see it in context.
ILMN stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $271.04 is 11.4% above the 50-day simple moving average of $243.41.Price above its 200-day average ›
The price is 56.2% above the 200-day simple moving average of $173.52.50-day average above the 200-day ›
The 50-day average ($243.41) is 40.3% above the 200-day average ($173.52), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 82% of its 52-week range, between $94.00 and $309.35.
ILMN share price
Pick a period: each tab shows how far ILMN has moved over it, to the last close.
Today's trading
Where ILMN sits inside today's range and its 52-week range.
ILMN fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/4P/E below the sector median ›
The trailing P/E of 50.57 is 58.5% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 9.32 is 174.0% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $853.0M on revenue of $4.4B, a net margin of 19.4%.Beat estimates in most recent reports ›
ILMN beat the EPS estimate in 5 of the 5 reports in our data.
Key statistics
The headline figures for ILMN.
As of October 26, 2026, ILMN trades at $271.04, with a market value of $40.93B and a P/E ratio of 50.57.
What the numbers say
CleaRank Financial AI's reading of ILMN's valuation, growth and risks.
Illumina Inc. (ILMN) has a trailing P/E of 50.57, which is 57.6% above the Healthcare median of 31.9. The peer comparison on this page gives it a premium to peers. To put its size in context, the market capitalisation is $40.9B.
Profitability shows a net margin of 19.4% and an operating margin of 21.14%, with a return on equity of 32.34%, above the sector median of 7.3%. The balance sheet rounds out the picture, with debt-to-equity of 0.89.
ILMN earned $1.15 per share against an analyst estimate of $1.05 in the April 30, 2026 report, beating the estimate by 9.52%. In the first session after that report, the share price rose 7.13%.
ILMN has beaten the EPS estimate in all 5 reports in our data; even so, 3 of those 5 beats were followed by a lower share price the next session. Earlier, the stock rose 24.78% after the October 30, 2025 report, a beat of 14.53%. Looking ahead, analysts expect EPS of $5.36 this fiscal year (growth of 10.7%) and $6.13 the year after (growth of 14.4%).
ILMN typically moves about 3.47% a day, and its beta against the S&P 500 is 1.42. A P/E of 50.57 sits 58.5% above the sector median, which is a premium to peers, so any disappointing results would face a demanding bar. Over the last 18 months insiders sold $592.9M of stock and bought $1.6M. Sales of this kind are often planned in advance or made to cover tax on vesting shares, so they tell less than purchases do.
ILMN against the Healthcare sector
How ILMN compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: ILMN trades at a significant premium to sector peers (+59%), suggesting market expectations for superior growth or market position.
Return vs XLV: Since May 14, 2025, ILMN has gained 246.6% against a gain of 39.2% for XLV.
Performance against XLV
ILMN and the Healthcare sector fund over the same days.
Revenue and earnings
How much ILMN sells, and how much of it becomes profit.
Revenue growth: Revenue fell 0.7% in FY2025 to $4.3B, from $4.4B a year earlier.
Profit margin: The net margin was 19.6% in FY2025, up from -28.0% the year before.
Profitable: ILMN earned $850M in FY2025.
Earnings reality check
Did ILMN beat what analysts expected, and how did the stock react?
Earnings record: ILMN beat the analyst estimate in 5 of the 5 reports in our data.
Market reaction: The stock fell in the first session after 3 of those 5 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Apr 30, 2026after close | $1.05 | $1.15 | +9.52% | +7.13% | +9.44% |
| Feb 5, 2026after close | $1.23 | $1.35 | +9.76% | -10.40% | -14.35% |
| Oct 30, 2025after close | $1.17 | $1.34 | +14.53% | +24.78% | +22.32% |
| Jul 31, 2025after close | $1.01 | $1.19 | +17.82% | -7.84% | -7.02% |
| May 8, 2025after close | $0.94 | $0.97 | +3.19% | -4.80% | +1.66% |
Reports after April 30, 2026 are not yet in our data.
As of October 26, 2026, ILMN has beaten the analyst EPS estimate in 5 of the 5 reports in our data and fell in the first trading session after 3 of those beats; its most recent report in our data, on April 30, 2026, came in 9.52% above the estimate and the stock moved +7.13% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
ILMN AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 55.5, in neutral territory.RSI above 50 ›
An RSI of 55.5 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of ILMN
The score, the reasoning behind it, and what could move the price next.
ILMN is in an uptrend, with the price at $271.04 sitting 11.35% above its 50-day average of $243.41 and 56.20% above its 200-day average of $173.52. Illumina Inc. (ILMN) trades near the top of its 52-week range: the price is 12.38% below the high of $309.35 and 188.34% above the low of $94.00.
The recent returns are all positive: the price rose 43.05% over the past three months, rose 110.89% over the past six months and rose 170.74% over the past year. Volume in the last session ran 33.7% below its average, on a day the price rose 0.60%. The 14-day RSI of 55.5 is in the neutral zone, and the MACD line is positive.
Earnings beat ›
The April 30, 2026 report beat the EPS estimate by 9.52%, and the share price rose 7.13% in the first session after it.
Source: Earnings report, April 30, 2026
Rating reaffirmed ›
Canaccord Genuity kept its Hold rating on October 19, 2026.
Source: Analyst action, Canaccord Genuity, October 19, 2026
- The two levels to track are the 52-week high at $309.35, above the price, and the 20-day EMA at $266.52, below it.
- A 14-day RSI of 55.5 lands in the neutral zone, and the MACD line is positive. Readings above 70 or below 30 point to stretched momentum.
- The share price rose 7.13% in the first session after the April 30, 2026 report. ILMN has beaten estimates in 5 of the 5 reports in our data.
ILMN's uptrend depends on the price holding above its 50-day average of $243.41 and its 200-day average of $173.52. A close below the 50-day would be the first sign of that trend weakening. If the price pulls back, the first level it would reach is the 20-day EMA at $266.52.
The next level above the price is the 52-week high at $309.35.
Technical indicators
Momentum and trend for ILMN, from its daily closes.
As of October 26, 2026, with ILMN at $271.04, its 14-day RSI is 55.5 (neutral territory), its 50-day simple moving average is $243.41 and its 200-day is $173.52.
Calculated by CleaRank on daily closes as of October 26, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What ILMN moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 26, 2026, ILMN's 1-year correlation of daily returns is +0.37 with S&P 500 (SPY), +0.34 with Nasdaq 100 (QQQ), +0.12 with Bitcoin (BTC) and +0.07 with gold (XAU).
ILMN price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
10 of 21 analysts rate it a buy or strong buy, 7 a hold and 4 a sell.Median target above the price ›
The median 12-month target of $272.50 is 0.5% above the price.More buy ratings than three months ago ›
10 of 21 rate it a buy now, against 10 of 19 three months ago.
ILMN Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 19, 2026 | Canaccord Genuity | Maintains | Hold |
| Oct 13, 2026 | TD Cowen | Maintains | Hold |
| Oct 7, 2026 | Barclays | Maintains | Underweight |
| Oct 5, 2026 | RBC Capital | Maintains | Outperform |
| Oct 1, 2026 | Guggenheim | Maintains | Buy |
| Sep 29, 2026 | Leerink Partners | Maintains | Outperform |
As of October 26, 2026, 21 Wall Street analysts cover ILMN: 10 rate it a buy or strong buy, 7 a hold and 4 a sell or strong sell. Their 12-month price targets range from $113.00 to $365.00. The median ILMN price target is $272.50, 0.5% above the price of $271.04.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
ILMN trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
ILMN trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
ILMN moves about 3.5% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much ILMN tends to move, against the market and on its own.
ILMN price history and drawdowns
ILMN's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 3.47% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 86.0%, from August 2021 to April 2025; the price is still 46.0% below that peak.Most 1-year holds ended higher ›
52% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $20,004, against $42,015 in the S&P 500 (SPY).
ILMN Drawdowns & Recovery
As of October 26, 2026, ILMN's worst peak-to-trough fall over the last 10 years with dividends reinvested was -86.0% (August 2021 to April 2025); it is still 46.0% below that peak, and 52% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into ILMN in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: ILMN trailed the S&P 500 over this period: $20,004 against $42,015.
A $10,000 investment in ILMN in October 2016 would be worth about $20,004 today with dividends reinvested, compared with about $42,015 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to ILMN, and which have not.
Strongest month, January: an average of +5.51%, up in 6 of 10 years.
Weakest month, February: an average of -5.30%, up in 2 of 10 years.
This month, October: has averaged +4.56%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, ILMN's strongest calendar month has been January (average +5.51%, up in 6 of 10 years) and its weakest February (average -5.30%, up in 2 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
ILMN stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in ILMN, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in ILMN today could grow to about $12,947 by 2030 in the base case, with a 90th-percentile outcome near $37,891 and a 10th-percentile outcome around $4,424. Projections are statistical simulations, not guarantees.
ILMN Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $351 for ILMN by 2030 in the base case, from $271 today (1.3x over 4 years). The 10th-percentile path ends near $120. These are outcomes of a Monte Carlo simulation run on ILMN's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $169 | $289 | $495 | |
| 2028 | $144 | $308 | $659 | |
| 2029 | $130 | $329 | $834 | |
| 2030 | $120 | $351 | $1,027 |
Method: a lognormal simulation of ILMN's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
ILMN insider trading
What the people running the company have bought and sold.
ILMN insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $1.6M on the open market and sold $592.9M.
As of October 26, 2026, ILMN insiders reported 18 open-market sales worth $592.9M and 4 open-market purchases worth $1.6M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Julie Ann Coletti
Officer
|
Grant | 18.8K | - |
| Sep 4, 2026 | Keith A Meister
Director
|
Sell | 263.6K | $57.2M |
| Aug 27, 2026 | Keith A Meister
Director
|
Sell | 375.9K | $85.2M |
| Aug 21, 2026 | Keith A Meister
Director
|
Sell | 679.6K | $145.6M |
| Aug 18, 2026 | Christensen Jakob Wedel
Officer
|
Sell | 1.0K | $197.8K |
| Aug 5, 2026 | Keith A Meister
Director
|
Sell | 741.1K | $148.2M |
| Aug 5, 2026 | Michael C Sullivan
Officer
|
Grant | 4.5K | $900.0K |
| Jul 30, 2026 | Scott M Davies
Officer
|
Sell | 615 | $123.0K |
| Jun 30, 2026 | Keith A Meister
Director
|
Grant | 142 | $21.2K |
| Jun 30, 2026 | Scott B Ullem
Director
|
Grant | 167 | $24.9K |
| Jun 25, 2026 | Scott M Davies
Officer
|
Sell | 615 | $110.7K |
| Jun 16, 2026 | Daniel Skovronsky
Director
|
Grant | 1.7K | $275.0K |
| Jun 5, 2026 | Patricia L Leckman
Officer
|
Sell | 783 | $127.3K |
| Jun 2, 2026 | Patricia L Leckman
Officer
|
Sell | 784 | $127.1K |
| Jun 1, 2026 | Keith A Meister
Director
|
Sell | 669.6K | $107.0M |
| May 29, 2026 | Scott D Ericksen
Officer
|
Sell | 2.0K | $305.2K |
| May 29, 2026 | Scott M Davies
Officer
|
Sell | 615 | $98.4K |
| May 28, 2026 | Keith A Meister
Director
|
Option | 24.6K | $2.5M |
| May 21, 2026 | Caroline D Dorsa
Director
|
Grant | 2.1K | $300.1K |
| May 21, 2026 | Scott Gottlieb
Director
|
Grant | 2.1K | $300.1K |
| May 21, 2026 | David P King
Director
|
Grant | 2.1K | $300.1K |
| May 21, 2026 | Keith A Meister
Director
|
Grant | 2.1K | $300.1K |
| May 21, 2026 | Anna S. Richo
Director
|
Grant | 2.1K | $300.1K |
| May 21, 2026 | Philip W Schiller
Director
|
Grant | 2.1K | $300.1K |
| May 21, 2026 | Susan E Siegel
Director
|
Grant | 2.1K | $300.1K |
| May 21, 2026 | Scott B Ullem
Director
|
Grant | 2.1K | $300.1K |
| May 14, 2026 | Keith A Meister
Director
|
Sell | 329.5K | $47.9M |
| May 12, 2026 | Keith A Meister
Director
|
Option | 255.4K | $26.3M |
| May 11, 2026 | Keith A Meister
Director
|
Option | 88.8K | $9.1M |
| May 6, 2026 | Christensen Jakob Wedel
Officer
|
Sell | 700 | $97.3K |
| Mar 31, 2026 | Keith A Meister
Director
|
Grant | 161 | $21.2K |
| Mar 31, 2026 | Scott B Ullem
Director
|
Grant | 190 | $25.0K |
| Mar 5, 2026 | Steven Barnard
Chief Technology Officer
|
Grant | 7.6K | $975.0K |
| Mar 5, 2026 | Scott M Davies
Officer
|
Grant | 5.8K | $750.1K |
| Mar 5, 2026 | Ankur Dhingra
Chief Financial Officer
|
Grant | 9.4K | $1.2M |
| Mar 5, 2026 | Scott D Ericksen
Officer
|
Grant | 3.2K | $412.5K |
| Mar 5, 2026 | Patricia Leckman
Officer
|
Grant | 6.3K | $810.1K |
| Mar 5, 2026 | Kevin Carl Pegels
Officer
|
Grant | 6.3K | $810.1K |
| Mar 5, 2026 | Jacob Thaysen
Chief Executive Officer
|
Grant | 25.7K | $3.3M |
| Mar 5, 2026 | Christensen Jakob Wedel
Officer
|
Grant | 5.6K | $720.1K |
| Feb 20, 2026 | Scott M Davies
Officer
|
Sell | 1.3K | $155.2K |
| Feb 18, 2026 | Patricia Leckman
Officer
|
Sell | 2.4K | $275.3K |
| Feb 12, 2026 | Steven Barnard
Chief Technology Officer
|
Grant | 2.7K | - |
| Feb 12, 2026 | Scott M Davies
Officer
|
Grant | 1.4K | - |
| Feb 12, 2026 | Scott D Ericksen
Officer
|
Grant | 743 | - |
| Feb 12, 2026 | Patricia Leckman
Officer
|
Grant | 1.0K | - |
| Feb 12, 2026 | Kevin Carl Pegels
Officer
|
Grant | 2.3K | - |
| Feb 12, 2026 | Jacob Thaysen
Chief Executive Officer
|
Grant | 13.3K | - |
| Feb 9, 2026 | Scott Gottlieb
Director
|
Buy | 200 | $23.6K |
| Dec 31, 2025 | Scott B Ullem
Director
|
Grant | 212 | $24.9K |
| Dec 12, 2025 | Scott M Davies
Officer
|
Sell | 323 | $44.0K |
| Dec 8, 2025 | Christensen Jakob Wedel
Officer
|
Sell | 549 | $71.0K |
| Nov 3, 2025 | Scott Gottlieb
Director
|
Buy | 500 | $61.1K |
| Sep 30, 2025 | Scott B Ullem
Director
|
Grant | 252 | $25.0K |
| Jun 30, 2025 | Scott B Ullem
Director
|
Grant | 307 | $24.9K |
| May 21, 2025 | Frances H Arnold, PH.D.
Director
|
Grant | 3.8K | - |
| May 21, 2025 | Caroline D Dorsa
Director
|
Grant | 3.8K | - |
| May 21, 2025 | Robert S Epstein
Director
|
Grant | 3.8K | - |
| May 21, 2025 | Scott Gottlieb
Director
|
Grant | 3.8K | - |
| May 21, 2025 | Gary S Guthart
Director
|
Grant | 3.8K | - |
| May 21, 2025 | Keith A Meister
Director
|
Grant | 3.8K | - |
| May 21, 2025 | Anna S. Richo
Director
|
Grant | 3.8K | - |
| May 21, 2025 | Philip W Schiller
Director
|
Grant | 3.8K | - |
| May 21, 2025 | Susan E Siegel
Director
|
Grant | 3.8K | - |
| May 21, 2025 | Scott B Ullem
Director
|
Grant | 3.8K | - |
| May 13, 2025 | Jacob Thaysen
Chief Executive Officer
|
Buy | 12.4K | $998.7K |
| May 12, 2025 | Ankur Dhingra
Chief Financial Officer
|
Buy | 6.1K | $495.4K |
Source: TwelveData, from SEC Form 4 filings
ILMN stock forecast: questions people ask
Answered from the figures on this page, as of October 26, 2026.